Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 2/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.33 |
| ▸ | RET | P07949 | 2/20 | 0.33 |
| ▸ | ROS1 | P08922 | 2/20 | 0.33 |
| ▸ | FLT3 | P36888 | 2/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.32 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAT2A | P31153 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | GPR6 | P46095 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL394569 | 1.00 | CHRM4 (0.36) | CHRM4ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL395556 | 0.93 | PIK3CA (0.39) | CHRM4PIK3CARETROS1FLT3 | |
| SCHEMBL395555 | 0.93 | PIK3CA (0.39) | CHRM4PIK3CARETROS1FLT3 | |
| SCHEMBL13227978 | 0.86 | SYK (0.35) | CHRM4ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL7921207 | 0.86 | SYK (0.35) | CHRM4ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL1984278 | 0.82 | CHUK (0.40) | ADORA2AADORA1RETROS1FLT3 | |
| SCHEMBL1984281 | 0.82 | CHUK (0.40) | ADORA2AADORA1RETROS1FLT3 | |
| SCHEMBL1984275 | 0.82 | CHUK (0.40) | ADORA2AADORA1RETROS1FLT3 | |
| SCHEMBL8202941 | 0.82 | CHUK (0.40) | ADORA2AADORA1RETROS1FLT3 | |
| SCHEMBL1984570 | 0.79 | MAPK8 (0.40) | PIK3CAMAPK8MAPK9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130343988-A1 | Pyrido [2, 3-D] pyrimidin-7-one compounds as inhibitors of P13K-Alpha for the treament of cancer | EXELIXIS, INC. (US) | 2013-12-26 | — | — | US | disclosed |
| EP-2142544-B1 | PYRIDO [2, 3-D]PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF PI3K-ALPHA FOR THE TREATMENT OF CANCER | EXELIXIS INC (US) | 2013-05-22 | — | — | EP | disclosed |
| US-8101622-B2 | Pyridopyrimidinone inhibitors of PI3Kα and mTOR | EXELIXIS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2350070-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3K AND MTOR | Exelixis, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| EP-2240454-A1 | MESOIONIC PESTICIDES | E. I. du Pont de Nemours and Company (US) | 2010-10-20 | — | — | EP | disclosed |
| US-20100209340-A1 | PYRIDO [2, 3-D] PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF P13K-ALPHA FOR THE TREATMENT OF CANCER | EXELIXIS, INC. | 2010-08-19 | — | — | US | disclosed |
| US-20100087456-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3K-ALPHA and mTOR | EXELIXIS, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| WO-2010039740-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα AND MTOR | EXELIXIS, INC. (US) | 2010-04-08 | — | — | WO | disclosed |
| EP-2142544-A1 | PYRIDO [2, 3-D]PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF PI3K-ALPHA FOR THE TREATMENT OF CANCER | Exelixis, Inc. (US) | 2010-01-13 | — | — | EP | disclosed |
| WO-2009099929-A1 | MESOIONIC PESTICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-08-13 | — | — | WO | disclosed |
| WO-2008127712-A1 | PYRIDO [2, 3-D] PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF PI3K-ALPHA FOR THE TREATMENT OF CANCER | EXELIXIS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130343988-A1 | Pyrido [2, 3-D] pyrimidin-7-one compounds as inhibitors of P13K-Alpha for the treament of cancer | CDKN1A, MAP3K3, CCNK | CHRM4 4779/4885ADORA3 2160/4885ADORA2A 3397/4885 |
| US-20100087456-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3K-ALPHA and mTOR | PIK3CD, PIK3CA, MTOR | CHRM4 4873/4885ADORA3 2478/4885ADORA2A 2741/4885 |
| US-20100209340-A1 | PYRIDO [2, 3-D] PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF P13K-ALPHA FOR THE TREATMENT OF CANCER | CDKN1A, CCNK, MAP3K3 | CHRM4 4674/4885ADORA3 2577/4885ADORA2A 3762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.